Hormonal Contraception in Healthy Young Men (P42306)(COMPLETED)(P06057)
Phase 2
Completed
- Conditions
- Contraception
- Interventions
- Drug: Placebo
- Registration Number
- NCT00403793
- Lead Sponsor
- Organon and Co
- Brief Summary
Male volunteers receive a new hormonal contraceptive consisting of an implant releasing a hormone and hormone injections in order to investigate the suppressive effect on sperm production and reversibility of sperm production after end of treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 350
Inclusion Criteria
- Male
- Mentally and physically healthy
- BMI between 18 and 32 kg/m^2
- Two pre-treatment semen samples > 20 million/ml with normal morphology and motility
Exclusion Criteria
- History or presence of psychiatric disease, liver disease, renal disease, diabetes, cardiovascular disease, any malignancy, prostatic disease, or genitourinary infection
- PSA > 2.5 ng/ml
- Use of drugs known to interfere with pharmacokinetics of steroids
- Use of lipid-lowering drugs
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm 2 Placebo Placebo Arm 1 etonogestrel with testosterone undecanoate etonogestrel with testosterone undecanoate
- Primary Outcome Measures
Name Time Method % of men who had a sperm concentration of 1 million/ml or less at week 16. Week 16
- Secondary Outcome Measures
Name Time Method Semen Parameters At several timepoints during treatment Reversibility of Suppression Post-Treatment Hormones At several timepoints Pharmacokinetics At several timepoints Safety At several timepoints
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie etonogestrel and testosterone undecanoate's suppression of spermatogenesis in NCT00403793?
How does the etonogestrel-testosterone undecanoate combination compare to standard male contraceptive methods in efficacy and safety profiles?
Which biomarkers predict individual response to subcutaneous etonogestrel and intramuscular testosterone undecanoate in male contraception?
What adverse events were reported in NCT00403793's Phase IIb trial of hormonal male contraception and how were they managed?
What are the competitive hormonal contraceptive strategies or compounds in development compared to Organon's etonogestrel-testosterone undecanoate approach?